About IGM Biosciences, Inc. IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com. Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).
External link for IGM Biosciences, Inc.
325 E Middlefield Rd
Mountain View, California 94043, US
IGM Biosciences, Inc. reposted this
IGM Biosciences, Inc. is seeking a Sr. Director of Regulatory Affairs to serve as the global regulatory lead (GRL) on several immunology programs. This role involves developing global regulatory strategies and implementing them for our expanding pipeline of autoimmune programs. #IGMS #autoimmune #autoimmunediseases #immunology #rheumatology #regulatoryaffairs
IGM Biosciences, Inc. reposted this
Join our team! We are seeking a cross-functional collaborative Director, Supply Planning and Project Management with skills in clinical supply management, long-range planning, and tech transfer. hashtag #IGMS #clinicalsupply #GMProjectmanagement #biotechtransfer
As we mark #WorldLupusDay, IGM recognizes the millions of people worldwide impacted by #lupus, including their families and friends. We are inspired to advance our research in SLE, RA, myositis, and other autoimmune diseases. #MakeLupusVisible; #LupusAwarenessMonth; #IGMLupus
IGM Biosciences, Inc. reposted this
We are thrilled to introduce our 2024 Greater Philadelphia #StudentVisionariesOfTheYear Leadership Committee Co-Chair, Sean Ahern, PharmD, RPh! Sean is currently an Associate Director, Clinical Scientist at IGM Biosciences, Inc.. He earned his Doctor of Pharmacy from Philadelphia College of Pharmacy at Saint Joseph’s University. This will be Sean’s third year with Student Visionaries. He is excited to meet and work with the 2024 candidate class! We are grateful to Sean’s ongoing commitment to developing the future generation of changemakers and bringing us closer to a cure. Thank you, Sean! To get involved with Student Visionaries, check out our website 👉 https://lnkd.in/g_smrzxq #LLSVisionaries #LLSEPADE